IRB Study Number 18-380
Status Recruiting
Location Cleveland Clinic Main Campus
Institute Taussig Cancer Institute
Description
The aim of this study is to prospectively determine outcomes of alloHCT in Medicare beneficiaries with Stage II and III MM and to compare those outcomes to similar patients receiving autoHCT, a standard therapy currently reimbursed by CMS. The study will further determine if these outcomes among ≥ 65 year old patients are similar to <65 year old beneficiaries. Lastly, this study will also evaluate patient, disease and treatment factors which might modify transplant outcomes.
Inclusion Criteria
- Medicare beneficiaries
- Have Stage II or III multiple myeloma
- Are eligible to receive an alloHCT from any suitable allogeneic donor (as determined by the transplant center) including umbilical cord blood
- Being treated in a US transplant center
- Provide informed consent to participate in the study
Exclusion Criteria
none
